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Abstract: We report the synthesis and relevant pharmacological properties of the quinoxalinetacrine
(QT) hybrid QT78 in a project targeted to identify new non-hepatotoxic tacrine derivatives for
Alzheimer’s disease therapy. We have found that QT78 is less toxic than tacrine at high concentrations
(from 100 µM to 1 mM), less potent than tacrine as a ChE inhibitor, but shows selective BuChE
inhibition (IC50 (hAChE) = 22.0 ± 1.3 µM; IC50 (hBuChE) = 6.79 ± 0.33 µM). Moreover, QT78 showed
effective and strong neuroprotection against diverse toxic stimuli, such as rotenone plus oligomycin-A
or okadaic acid, of biological significance for Alzheimer’s disease.
Keywords: Alzheimer’s disease; cholinesterase inhibitor; hepatotoxicity; molecular modeling;
neuroprotection; quinoxalines; quinoxalinetacrines; tacrine
1. Introduction
Alzheimer’s disease (AD) is the most common neurodegenerative disorder. Many biochemical
hallmarks are involved in the progress and development of this pathology: extracellular senile
plaques that appear by amyloid-beta peptide deposition and aggregation, hyperphosphorylated
tau-protein, neuroinflammation, cell death, oxidative stress, and a strong deficit of neurotransmitters
such as acetylcholine, dopamine, and serotonin [1]. These facts have resulted in what has been
called the “cholinergic hypothesis of AD”, highlighting that most AD patient impairments are due
to deficient cholinergic neurotransmission [2]. Consequently, a few acetylcholinesterase (AChE) and
butyrylcholinesterase (BuChE) inhibitors (rivastigmine, donepezil, galantamine) have been identified
and are currently being used in clinical treatment for the therapy of AD [3]. The finding that BuChE
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activity is raised in AD, and that BuChE activity is concentrated in areas of the brain engaged in
cognition, suggests the use of selective BuChE inhibitors for AD therapy [4]. Unfortunately, to date,
no effective treatment has been discovered to cure this pathology. Consequently, there is an urgent
need for novel and more efficient drugs to treat AD patients. In the search for new therapies to deal
with this complex and multifactorial disease, the multitarget small molecule (MTSM) approach [5] is
considered one of the most attractive therapeutic strategies.
In this context, and pursuing our search for non-hepatotoxic tacrine (Figure 1) analogues [6]
showing ChE inhibition, we designed the quinoxalinetacrines (QTs) (I, Figure 1) as new, simple, and
readily available agents. Quinoxalines are a class of molecules endowed with a large of array of
biological properties, including anti-neuroinflammation, antitumoral, antimycobacterial, and antifungal
activities [7].
In this article, we describe the synthesis, toxicological and neuroprotective properties, as well as
the computational analysis of QT78 (1,2,3,4-tetrahydroquinolino[2,3-b]quinoxalin-12-amine) (Figure 1),
as the first member of this new family of QT derivatives.
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The synthesis of QT78 has been carried out as shown in scheme 1, with a good yield, by reacting 
3-amino-2-quinoxalinecarbonitrile [8] and cyclohexanone, under typical Friedländer-type reaction 
conditions [9,10]. QT78 showed spectroscopic data in good agreement with its structure and excellent 
analytical data (see Supporting Information). It is interesting to note that Hamama and co-workers 
have recently reported the reaction of 2-amino-3-cyano-6-methylquinoxaline-1,4-dioxide with several 
cycloalkanones, and described their antibacterial, antifungal, and antitumor activities [11]. 
 
Scheme 1. Synthesis of QT78. 
First, we started with the in silico toxicological analysis [12]. In order to predict the hepatotoxic 
potential of QT78, and its main Phase I metabolites, we performed the in silico analysis of QT78. The 
result for hepatotoxicity was “nothing to report”, showing that there is not enough evidence to 
predict a positive/negative result. This means that, structurally, the novel compound is quite different 
to tacrine, and consequently, QT78 does not provide any positive prediction of hepatotoxicity. 
Likewise, its ten Phase I metabolites displayed the same message, indicating that there was no 
associated tacrine metabolites risk (Figure 2). 
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2. Results and Discussion
The synthesis of QT78 has been carried out as shown in Scheme 1, with a good yield, by reacting
3-amino-2-quinoxalinecarbonitrile [8] and cyclohexanone, under typical Friedländer-type reaction
conditions [9,10]. QT78 showed spectroscopic data in good agreement with its structure and excellent
analytical data (see Supporting Information). It is interesting to note that Hamama and co-workers
have recently reported the reaction of 2-amino-3-cyano-6-methylquinoxaline-1,4-dioxide with several
cycloalkanones, and described their antibacterial, antifungal, and antitumor activities [11].
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First, we started with the in silico toxicological analysis [12]. In order to predict the hepatotoxic
potential of QT78, and its main Phase I metabolites, we performed the in silico analysis of QT78.
The result for hepatotoxicity was “nothing to report”, showing that there is not enough evidence to
predict a positive/negative result. This means that, structurally, the novel compound is quite different to
tacrine, and consequently, QT78 does not provide any positive prediction of hepatotoxicity. Likewise,
its ten Phase I metabolites displayed the same message, indicating that there was no associated tacrine
metabolites risk (Figure 2).
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Thus, we chose HepG2 cells, a well-established in vitro model and widely used human hepatoma
cell line [13], to test the hepatotoxicity exerted by QT78, using tacrine as the reference drug. Cells were
incubated with QT78 and tacrine in a wide range of doses (1–1000 µM) in a 24 h period. The HepG2
viability was significantly decreased when QT78 was incubated at the highest concentrations (300 and
1000 µM) (Table 1). However, the toxicity profile was significantly better than that of tacrine, which
showed a significant viability reduction at lower concentrations (from 30 µM). These results suggest
that the hepatotoxic safety profile of QT78 is better than that of tacrine (Supporting Information).
Table 1. In vitro hepatotoxicity of tacrine and QT78 in HepG2 cells.
Compounds Viability (%) HepG2 Cells
1 µM 3 µM 10 µM 30 µM 100 µM 300 µM 1000 µM
QT78 96.7 ± 2.14 ns 97.6 ± 2.20 ns 97.1 ± 1.64 ns 95.1 ± 1.50 ns 90.5 ± 1.86 ns 78.1 ± 0.94 *** 68.3 ± 2.92 ***
Tacrine 93.4 ± 4.69 ns 90 ± 2.95 ns 88.7 ± 3.42 ns 81.6 ± 4.88 * 64.3 ± 4.54 *** 40 ± 2.20 *** 34.4 ± 2.73 ***
Cell viability was measured as MTT reduction and data were normalized as % control. Data are expressed as
the means ± S.E.M. in triplicate of at least three different cell batches. All compounds were assayed at increasing
concentrations (1–1000µM). *** P< 0.001, * P< 0.05 and ns not significant, with respect to control group. Comparisons
between drugs and control group were performed by one-way ANOVA followed by the Newman–Keuls post-hoc test.
Next, the in vitro inhibition of human acetylcholinesterase (hAChE) and human
butyrylcholinesterase (hBuChE) was assessed according to the method of Ellman [14] (Supporting
Information), using tacrine as the reference compound. Comparison of the IC50 values highlighted
that QT78 acts as a modest but selective hBuChE inhibitor [IC50 (hAChE) = 22.0 ± 1.3 µM; IC50
(hBuChE) = 6.79 ± 0.33 µM]. Thus, it is obvious that the enlargement of the three-membered
tetrahydroacridine scaffold to the four-membered tetrahydroquinolino[2,3-b] quinoxaline nucleus was
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detrimental regarding its activity towards both ChE enzymes, leading to a decrease of the inhibitory
potency of two orders of magnitude (tacrine: IC50 (hAChE) = 0.374 ± 0.053 µM; IC50 (hBuChE) = 0.044
± 0.002 µM) [10]. Based on these results, we next carried out docking studies to explain the binding
modes of compound QT78 in hAChE and hBuChE.
The structures of hAChE crystallized with fasciculin II (PDB ID: 1B41) and hBuChE crystallized
with tacrine (PDB ID: 4BDS) were used. The docking of compound QT78 with the target enzymes
was performed using AutoDock Vina [15] software and the results were analyzed with Discovery
Studio. As we have previously described [10], the conformational flexibility of AChE was considered
by allowing eight side chains to be flexible during the docking process.
Regarding hAChE, compound QT78 is accommodated in the middle of the active-site gorge
and no interaction with the catalytic triad aminoacids (His447, Ser203 and Glu334) is established.
The cyclohexane ring is oriented towards the bottom of the gorge, establishing pi-alkyl interactions
with Trp86, a residue involved in the interaction with the quaternary amine of the natural ligand ACh.
The complex AChE-QT78 was also stabilized by molecular interactions with several key residues at
the peripheral anionic site (PAS). There is a hydrogen bond network in which the amino group and
the pyrazine nitrogen with Tyr124 and Asp74 are involved. Additionally, the phenyl ring forms a pi-pi
stacking interaction with Tyr341 and the pyridine ring forms a pi-pi T-shaped interaction with Tyr337
(Figure 3a,b). To sum up, we propose that compound QT78 interacts with the PAS of AChE without
catalytic triad residue involvement.
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Docking within hBuChE shows that compound QT78 is deeply inserted into the active site. 
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Figure 3. (a) Three-dimensional representation of interactions established by QT78 with hAChE. (b)
Two-dimensional schematic view of the interactions between QT78 and hAChE.
Docking within hBuChE shows that compound QT78 is deeply inserted into the active site.
Nevertheless, it can be seen that the structure of the docked compound does not fit in the space
occupied by tacrine (Figure 4a), which could account for its weaker BuChE inhibitory activity. As shown
in Figure 4b, the binding mode of compound QT78 is characterized by the following features: the NH2
group forms two hydrogen bonds with the catalytic triad residues His438 and Ser198. Moreover,
the pyridine and cyclohexane rings interact with the residues in the acyl-binding pocket (ABP) (Phe329
Molecules 2019, 24, 1503 5 of 12
and Leu286). Also, the pyridine ring allowed an amide-pi stacked interaction with Gly116 in the
oxyanion hole (OH).
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The molecular docking results show that QT78 is located in the active site of both enzymes, but in
hBuChE, the ligand interacts with the catalytic triad residues, whereas in hAChE the ligand is further
away. These results agree with the experimental results, which showed that QT78 is a modest but
selective hBuChE inhibitor.
In addition, for essential biological activity, drug candidates should also have an ideal
pharmacokinetic profile. In this context, we have computed Lipinski’s rule of five and other
pharmacokinetic properties of QT78, using the QikProp module of Schrödinger software (QikProp,
version 3.8, Schrodinger, LLC, New York, NY, USA, 2013).
Compounds violating more than one of these rules may have bioavailability limitations. The ADME
predictions of compound QT78 showed satisfactory results highlighting drug-like characteristics based
on Lipinski’s rule of five (see Table S1, Supporting Information) [16].
The drugs used for neurological disorder treatment act on the central nervous system (CNS).
CNS drugs show values of MW < 450, hydrogen-bond donors < 3, hydrogen-bond acceptors < 7,
number of hydrogen bond donor < 5, van der Waals surface area of polar nitrogen and oxygen atoms <
90, number of rotatable bonds < 8 and hydrogen bonds < 8. QT78 satisfied all the characteristic of
CNS acting drugs.
The aqueous solubility (QPlogS) of organic compounds plays a key impact on many ADME-related
properties. The solubility val e of QT78 (QPlogS = −3.746) was within the limits (−6.5–0.5). Further,
the predicted value for the partition coefficient (QPlogPo/w = 2.534), critical for the estimation of
absorption within the body, is in the optimum range (−2.0–6.5).
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Drugs must cross the blood–brain barrier (BBB) to exert their activity on the CNS; thus, one of
the most used descriptors for CNS penetration is logBB. Experimental values of log BB cover a span
from about −2.00 to +1.04. Within this range, compounds with log BB > 0.30 cross BBB readily, while
compounds with a log BB < −1.00 are poorly distributed into the brain [17]. The QPlogBB value for
QT78 is −0.332, indicating it has a good potential for BBB penetration.
The literature data suggest that polar surface area (PSA) is a measure of the hydrogen bonding
capacity of a molecule, and its value should not exceed a certain limit if the compound is intended
to be CNS active. The most active CNS drugs have a PSA lower than 70 A2. The value of PSA for
QT78 is 59.549 Å2, suggesting a good penetration of the BBB. Similarly, the percentage of human oral
absorption is very high (100%), while other physicochemical descriptors obtained by QikProp (Table S1,
Supporting Information) are within the acceptable range for human use, thereby indicating that QT78
is a potential drug-like molecule and possible CNS drug.
Finally, following the protocols described in the Supporting Information, we evaluated the
neuroprotective profile of QT78 against two toxic insults related to neurodegeneration [18,19], using
melatonin (10 nM) as a reference compound: (a) a model of reactive oxygen species (ROS) generation,
based on the cocktail of the mitochondrial respiratory chain blockers rotenone and oligomycin A
(R/O), and (b) hyperphosphorylation of tau protein using okadaic acid (OA), a well-known protein
phosphatase inhibitor. As shown in Figure 5, QT78 revealed an interesting neuroprotective activity.
At the concentrations of 0.1 and 0.3 µM, QT78 produced a significant increase in cell viability against
R/O (16.7% and 21.4%, respectively). Similarly, QT78 at 0.1 µM showed a potent increase in cell
viability against OA (18.9%). In all cases, when we increased the concentration of the compound to 1
µM, the protective capacity decreased against all toxic stimuli tested.
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evaporator. Flash column chromatography was performed using silica gel 60 (230–400 mesh, Merck). 
Melting points were determined on a Kofler block and are uncorrected. IR spectra were obtained on 
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3. Materials and Methods
3.1. Chemistry Methods
Reactions were monitored by TLC using precoated silica gel aluminum plates containing a
fluorescent indicator (Merck, 5539, Kenilworth, NJ, United States). Detection was done by UV (254 nm)
followed by charring with sulfuric–acetic acid spray, 1% aqueous potassium permanganate solution
or 0.5% phosphomolybdic acid in 95% EtOH. Anhydrous Na2SO4 was used to dry organic solutions
during work-ups and the removal of solvents was carried out under vacuum with a rotary evaporator.
Flash column chromatography was performed using silica gel 60 (230–400 mesh, Merck). Melting points
were determined on a Kofler block and are uncorrected. IR spectra were obtained on a Perkin-Elmer
Spectrum One spectrophotometer (Waltham, MA, United States). 1H-NMR spectra were recorded with
a Varian VXR-200S spectrometer (Palo Alto, CA, United States), using tetramethylsilane as internal
standard and 13C-NMR spectra were recorded with a Bruker WP-200-SY (Billerica, MA, United States).
All the assignments for protons and carbons were in agreement with 2D COSY, HSQC, HMBC, and 1D
NOESY spectra. Values (*) can be interchanged. The purity of compounds was checked by elemental
analyses, conducted on a Carlo Erba EA 1108 apparatus (Sabadell, Spain), and co firmed o be >95%.
3.2. Synthesis of QT78
A mixture of 3-amin -2-quin xalinec rbonitrile [8] (160 mg, 0.94 mmol), cyclohexanone (146 µL,
1.41 mmol) an AlCl3 (186 mg, 1.41 mmol) in 1,2-dichloroethane (6 mL) was irradiated in a MW
apparatus at 95 ◦C, 250 W and 20 atm, for 2 . Then, the mixture wa cooled at 0 ◦C, diluted with
a mixture of H2O/THF (1:1), treated with NaOH 15% until basic, and extracted s veral times with
methylene chloride. The organic lay r was was ed with brine until neutral, dried with Na2SO4, filtered
and evaporated. The residue was purified by column chromatography (CH2Cl2/MeOH (from 1% to
5%)), affording 1,2,3,4-tetrahydroquinolino[2,3-b]quinoxalin-12-amine (QT78, Figure 6) (172 mg, 88%):
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mp 238–240 ◦C; IR (KBr) 3292, 2938, 1622, 1605, 1501, 1375, 1347, 1326, cm−1; 1H-NMR (300 MHz,
DMSO) δ 8.17 (dd, J= 2.1, 8.8 Hz, 2H, H7, H10), 8.01–7.70 (m, 2H, H8, H9), 7.10 (bs, 2H, NH2), 2.98–2.96
(m, 2H, H4), 2.69–2.56 (m, 2H, H1), 1.88–1.85 (m, 4H, H2, H3); 13C-NMR (75 MHz, DMSO) δ 165.8
(2C, C12, C4a), 148.9 (C5a), 147.5 (C11a), 144.2 (C10a)*, 140.0 (C6a)*, 131.0 (C9)**, 130.6 (C8)**, 129.3
(C7)***, 129.0 (C10)***, 110.3 (C12a), 34.5 (C4), 23.9 (C1), 22.3 (C2)*, 21.9 (C3)*; MS (EI) m/z (%): 250
[M+] (100), 235 (18). HRMS. Calc. for C15H14N4 (M + H)+: 251.12912. Found: 251.12989. Anal. Cald.
for C15H14N4: C, 71.98; H, 5.64; N, 22.38. Found: C, 71.75; H, 5.61; N, 22.15.
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3.3. In Silico Prediction Systems for Toxicology and Metabolism
Meteor Nexus (v.3.1.0, Lhassa Limited, Leeds, UK) and Derek Nexus (v.6.0.1, Lhassa Limited,
Leeds, UK) knowledge-based expert systems (Knowledge Bases: Meteor KB 2015 1.0.0, Derek KB
2015 1.0) were employed for metabolism and toxicity predictions [20,21]. Hepatotoxicity was selected
as an “end point”. Derek Nexus assesses predictions based on a summary of evidences, evaluating
alerts and estimating the likelihood of occurrence [21]. The compound was considered to have a
structural alert for the selected endpoint (hepatotoxicity) if the prediction in Derek Nexus™ was
‘certain’, ‘probable’, ‘plausible’ or ‘equivocal’. The predictions ‘doubted’, ‘improbable’, ‘impossible’,
‘inactive’ or ‘no alert’ were regarded as negative. When Derek has no knowledge on which to base a
prediction, the message “nothing to report” is displayed; this absence of evidence is not synonymous
with a prediction of inactivity.
The metabolism was predicted by Meteor Nexus version 3.1.0, (Lhasa ltd., Leeds, UK), a SAR
(structure-activity relationship) tool used to predict the likely metabolic fate of a chemical structure
through a knowledge-base composed of a biotransformation dictionary, rules and example metabolic
pathways. Meteor was setup for human Phase I biotransformation reactions, since in most cases the
reactive metabolites are generated particularly through Phase I metabolic reactions [22]. An absolute
reasoning biotransformation ranking method was applied as a qualitative rule-based approach to
evaluate the likelihood level (probable, plausible, equivocal, doubted, and improbable). The minimal
likelihood level selected was “plausible”, meaning that the weight of evidence supports the proposition.
All possible first and second-generation metabolites have been generated and afterwards processed for
hepatotoxicity predictions.
3.4. In Vitro Toxicity of QT78 and Tacrine in HepG2 Cells
The human hepatoma HepG2 cell line was kindly provided by the IdiPAZ Institute for Health
Research (Madrid, Spain). They were cultured in Eagle´s minimum essential medium (EMEM)
supplemented with 15 nonessential amino acids, 1 mM sodium pyruvate, 10 % heat-inactivated
FBS, 100 units/mL penicillin, and 100 µg/mL streptomycin (reagents from Invitrogen, Madrid, Spain).
Cultures were seeded into flasks containing supplemented medium and maintained at 37 ◦C in a
humidified atmosphere of 5% CO2 and 95% air. Culture media were changed every 2 days. Cells were
sub-cultured after partial digestion with 0.25% trypsin-EDTA. For assays, cells were subcultured in
96-well plates at a seeding density of 1 × 105 cells per well. When the cells reached 80% confluence,
the medium was replaced with fresh medium containing 1–1000 µM QT78 and tacrine, or 0.1% DMSO
as a vehicle control.
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3.5. Inhibition of Human AChE and BuChE
The ability of QT78 to inhibit human ChE activity was assessed using Ellman’s assay [14]. A Jasco
V-530 double beam spectrophotometer connected to a HAAKE DC30 thermostating system (Thermo
Haake, Vreden, Germany) was used. Stock solutions of the tested compound and reference compound
tacrine (1–2 mM) were prepared in methanol and water, respectively, and diluted in the same solvent
used to prepare stock solution. The assay solution consisted of a 0.1 M phosphate buffer, pH 8.0, with
the addition of 340 µM 5,5′-dithiobis (2-nitrobenzoic acid), 0.02 unit/mL human recombinant AChE or
BuChE from human serum (Sigma-Aldrich, Milan, Italy), and 550 µM substrate, i.e., acetylthiocholine
iodide or butyrylthiocholine iodide, respectively (Sigma-Aldrich, Milan, Italy). Either 50 µL of a
solution of the tested compound at increasing concentrations or 50 µL of solvent (methanol or water)
were added to the assay solution and preincubated at 37 ◦C with the enzyme for 20 min before the
addition of substrate. The rate of absorbance increase at 412 nm was followed for 3 min. In parallel,
blanks containing all components except the enzyme were prepared to account for the non-enzymatic
hydrolysis of the substrate. The reaction rates were compared and the percentage of inhibition due to
the presence of test compound was calculated. Each concentration was analyzed in duplicate/triplicate.
The percentage of inhibition of the enzyme activity due to the presence of inhibitor was calculated.
Inhibition plots were obtained for each compound by plotting the percentage of inhibition versus
the logarithm of inhibitor concentration in the assay solution. The linear regression parameters were
determined for each curve and the IC50 extrapolated.
3.6. Molecular Modeling
The structure of compound QT78 was built using Discovery Studio 2.1 [15]. The molecular
geometry of QT78 was energy-minimized using the adopted-based Newton–Raphson algorithm with
the CHARMm force field [23] with a convergence criterion for the energy gradient 0.01 kcal (mol-Å)−1.
The ligand was set up for docking with the help of AutoDockTools (ADT; version 1.5.4) to define the
torsional degrees of freedom to be considered during the docking process. All the rotatable bonds of
the ligand were allowed to rotate freely. The enzyme structure used for the calculations was the human
AChE (Protein Data Band code 1B41). To give flexibility to the binding site, residues lining the site
were allowed to move. These residues were Trp286, Tyr124, Tyr337, Tyr341, Tyr72, Asp74, Thr75, Trp86.
Docking calculations for hBuChE were performed following a similar protocol to that described before
for hAChE. The coordinates of hBuChE were obtained from the Protein Data Bank (PDB ID: 4BDS). For
docking purposes, initial proteins were prepared by removing all water molecules, heteroatoms, any
co-crystallized solvent and the ligand. Proper bonds, bond orders, hybridization and charges were
assigned using protein model tool in the Discovery Studio, version 2.1, software package. A CHARMm
force field was applied using the receptor ligand interactions tool in the Discovery Studio software
package. ADT was used to add hydrogens and partial charges for proteins using Gasteiger charges and
to generate the docking input files. AutoDock Vina software was employed for all the protein-ligand
calculations and they were applied to the whole protein target (blind docking). For hAChE, the grid
box was built with a resolution of 1 Å and 60 × 60 × 72 Å and it was positioned at the middle of the
protein (x = 116.546; y = 110.33; z = −134.181). For hBuChE, a grid box of 66 × 60 × 74 with grid
points separated 1 Å was positioned in the middle of the protein (x = 136.0; y = 123.59; z = 38.56).
The resultant structure files were analyzed using Discovery Studio.
3.7. Neuroprotection Studies in Human Neuroblastoma Cells
Human SH-SY5Y cells were maintained in a 1:1 mixture of Nutrient Mixture F-12 and Eagle´s
minimum essential medium (EMEM) supplemented with 15 nonessential amino acids, 1 mM sodium
pyruvate, 10% heat-inactivated FBS, 100 units/mL penicillin, and 100 µg/mL streptomycin. Cultures
were seeded into flasks containing supplemented medium and maintained at 37 ◦C in a humidified
atmosphere of 5% CO2 and 95% air. For assays, SH-SY5Y cells were sub-cultured in 96-well plates at a
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seeding density of 5 × 104 cells per well for 2 days. The cells were then incubated with 30 µM rotenone
and 10 µM oligomycin-A (R/O) or okadaic acid (20 nM) (Sigma-Aldrich, Madrid, Spain) according to
previous studies [18,19] with or without QT78 at different concentrations for 24 h. In this study, all
cells were used at a low passage number (<14).
3.8. Measurement of Cell Viability
MTT reduction was performed as described [24] for both HepG2 and SH-SY5Y human cell lines.
Briefly, 50 µL of the MTT labeling reagent, at a final concentration of 0.5 mg/mL, was added. After
incubation for 2 h, in a humidified incubator at 37 ◦C with 5% CO2 and 95% air (v/v), the supernatant was
removed, the obtained purple formazan product was re-suspended in 100 µL of DMSO. Colorimetric
determination of MTT reduction was measured in an ELISA microplate reader at 540 nm. Non-treated
cells were considered controls and were taken as 100% viability.
3.9. Statistical Analysis
Statistical analyses were performed using GraphPad Prism software (version 6, San Diego, CA,
USA). The data were analyzed by t-test or ANOVA with Tukey’s multiple comparison test, as indicated.
P values less than 0.05 were considered significant.
4. Conclusions
In the search for a new MTSM [5] for AD [25–27], the most common neurodegenerative disorder [28],
the design, synthesis and pharmacological properties of QT78, the parent compound of a new family of
tacrine derivatives bearing the quinoxaline heterocyclic ring core, was investigated. As a result, we have
identified QT78 as a promising hit compound, which is less toxic than tacrine at high concentrations
(from 100 µM to 1 mM), but less potent than tacrine as an inhibitor of both ChEs, with a modest
selectivity towards BuChE. At 0.1 and 0.3 µM, QT78 exhibited a significant neuroprotective effect
against different toxic stimuli, including ROS generation and hyperphosphorylation of tau protein.
In addition, computational analyses shed light into the toxicological profile, binding and ADME
properties of QT78. Taken together, the reported data are relevant to the search for new anti-AD agents.
Our work is now in progress to prepare and evaluate new, related QTs based on QT78. The results will
be reported elsewhere in due course.
Supplementary Materials: Supporting Information is available free of charge on the website and includes
Materials and Methods, NMR and HRMS spectra, and the ADME analysis.
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